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Abstract: The aim of the study has been evaluation of the pharmacokinetics of fenbendazole molecule, 
with the experimental protocol for drug testing, using a test (Anipratel) dose of 214.9 mg, compared with a 
reference (Cestal) dose of 200 mg (table 1). The researches was made on 10 healthy dogs (n=10) from Romanian 
shepherd bred. All the dogs received a single oral tablet with fenbendazol, in two phases, one time with product 
contain the test dose (200 mg), and after 14 days, a second administration using a test product in dose of 214.9 
mg. Before and after each administration of drugs, were collected blood samples at various time intervals: 0.0, 
0.5. 1.0, 1.5, 2.0, 4.0, 8.0, 12.0, 24.0, 36.0, and 48.0 hours. The pharmacokinetics of fenbendazole was 
characterized by reaching the maximum plasmatic concentration after oral administration in 1-2 hours with the 
limits between 104.7 and 8.2 ng/ml. The half-time values have the variation between 2.77 and 13.81 hours 
according with the active ingredient dose. The kidney clearance of fenbendazole revealed value between 101.98 
l/hors and 395.32 l/hours, those values being characteristic for the turnover and elimination of fenbendazole from 
the animal body. General and statistic analyze of followed pharmacological parameters revel the possibility that 




The doses, and especial the concentration of active ingredient at the target tissue, cause 
the link between the drugs and the receptors, obtaining the specific biological action. 
Measuring in vivo the concentration of active ingredient at the exact place of action is 
difficult, and the possibility to evaluate the biological response and therapeutic effect is 
limited (LeucuŃa, 1989). In order to have the possibility to evaluate the pharmacological effect 
of the drugs is indicating to measure the plasma (or other internal liquids) level of active 
ingredient, because the biological response is direct proportional with the plasmatic 
concentration. 
 
MATERIAL AND METHODS 
 
In order to evaluate the pharmacokinetics of fenbendazole molecule, we apply the 
experimental protocol for drug testing, using a test (Anipratel) dose of 214.9 mg, compared 
with a reference (Cestal) dose of 200 mg (table 1). The researches was made on 10 healthy 
dogs (n=10) from Romanian shepherd bred. All the dogs received a single oral tablet with 
fenbendazol, in two phases, one time with product contain the test dose (200 mg), and after 14 
days, a second administration using a test product in dose of 214.9 mg. Before and after each 
administration of drugs, were collected blood samples at various time intervals: 0.0, 0.5. 1.0, 




The experimental scheme  
Table 1 
Proceedings  Samples Phase I Period      7-14 days Phase II 
Final 
examination 
The study day -7.......1 0 1 2 3  0 1 2 3 ....+7 
Physical exam •          • 
Vital signs  •  •     •   • 
Clinical exam  •          • 
Hematology  •          • 
Urine exam •          • 
Serologic exam •           
Drug administration   •     •    




  • • •   • • •  
 
  
 The dogs healthy condition, was appreciating before and during the researches by using 
a specific clinical and laboratory tests knowing as PharmaQuest.  In order to perform these 
tests we used the semiotic techniques and laboratory references (Ghergariu et al., 2000; 
Papuc, 2005; Ognean and Cernea, 2006).  
 From the collected blood samples, we separated the plasma by centrifuging 10 minutes 
at 2000 rotation/minute. The obtained plasma was frizzing at -20ºC and sending to 
PharmaQuest Laboratory form Tg.Mureş in order to perform the plasma concentration using 
HPLC method with UV. The obtained data was processing by ANOVA program using 
software KINETIKA 4.4.1. 
Finally were determined the first, second and additional pharmacokinetic parameters for 
establishing the bioequivalence of the tested products. In the same time, we observed some 
safety parameters represented by side effects, clinical and laboratory testes and supervision 
exam.     
The statistical interpretation (ANOVA) was focused on: treatment, sequence, subjects 
and administration period. These calculations are based on logarithmic transformation of the 
first pharmacokinetics parameters, determined by 90% confidence interval of individual 




RESULT AND DISCUSSIONS 
 
 The obtained results were different according with the investigated parameters. The 
clinical exam of animals show that the healthy status was good, body temperature, pulse and 
respiration was between normal limits, and was not diagnosed major acute or chronic 
diseases. Because the animal group was homogenous, we consider that the mean 
hematological data is a marker for the healthy status. 
 The pharmacokinetic results obtained by the lab show different variation of quantify 








Pharmacokinetic dynamics of fenbendazole parameters  
Table 2. 
Post- therapeutic moment of  determination (h) 
0 0.5 1 1.5 2 4 8 24 48 Subject 





I test 0 11.1 12.6 18.8 104.7 59.8 28.3 12.1 0 9.59 114.87 
I reference 0 16 15.2 23.25 98.6 63.1 32.4 14.3 0 10.25 101.98 
II test 0 10.5 19.7 17.6 53.96 34.7 31.1 11.1 0 11.72 127.27 
II reference 0 15.2 22.1 26.4 48.6 35.2 25.2 0 0 6.55 207.62 
III test 0 16.3 39.9 82.8 23.9 13.9 11.2 0 0 5.97 393.34 
III reference 0 11.2 28.3 75.3 44.6 26.3 10.1 0 0 2.81 395.32 
IV test 0 13.3 23.5 39.6 57.8 25.2 20.4 0 0 4.43 290.26 
IV reference 0 11.2 19.6 41.3 48.2 26.3 19.4 0 0 4.92 291.49 
V test 0 18.6 70.8 76.6 67.8 72.8 14.9 0 0 2.77 205.85 
V reference 0 10.5 39.9 53.8 23.7 13.2 10.3 0 0 11.17 324.67 
VI test 0 40.1 47.8 42.6 38.3 35 28.4 0 0 13.81 118.76 
VI reference 0 21.3 50.2 53.1 32.4 25.1 16.8 0 0 6.4 273.36 
       - Maximum plasmatic concentration (ng/ml); T1/2 – half-life (h); CL – clearance (l/h) 
 
 
 According with the obtained data and statistic interpretations, we observed that the 
maximum plasmatic concentration is realized between 1-2 ours after oral administration of the 
drugs. This situation was obtained indifferently of animal group (reference or test), half-life or 
clearance of fenbendazole. It is important to mention that in first hour after fenbendazole 
administration, only one dog achieve the maximum plasmatic concentration (47.8 ng/ml). As 
general dominance, we can observe that at 1.5 hour the maximum plasmatic concentration 
was between 76.6 and 53,1 ng/ml. In the majority of dogs  the maximum plasmatic 
concentration was reach at 2 hours after fenbendazole oral administration with a value 
between 104.7 and 8,2 ng/ml.  
 The half-life of fenbendazole was determined by individual variation and the limits 
were between 2.77 – 13.81 hours (table 2). 
 The kidney clearance of fenbendazole offer essentials data for monitoring turnover and 
elimination of this drug from the animal body. The dynamic studies of the clearance reveal the 
high level of elimination of fenbendazole on the dogs treat with low dose, but we register also 
individual exceptions (table 2). The general analyze of the studied parameters indicated 
individual differences depending on dose and this reveal the possibility that the fenbendazole 
molecule from these tow products can be metabolized in different way. In the same time, the 
general tendency of plasmatic level of fenbendazole was to achieve the maximum level in the 
first 1-2 hours. After this interval, the tendency of plasmatic concentration goes down, so that, 
after 24-48 hours the active ingredient cannot be identify at the plasmatic level.   
 In order to verify the efficacy and the safety of drugs is possible to use to methods. The 
first one is to establish the therapeutically equivalence, but this method request a large number 
of animal, long period of drug (test and reference) administration, and for this reasons is not 
so used. The second method establishes the base bioequivalence comparing with the relative 
bioavailability. From this tow method, in the present, the second one is the most convenient. 
For the both method the safety and efficacy of the product must be proof. In the same line, we 
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mention that any therapeutic experiment present a potential risk, so is possible to promote a 
veterinary products without efficacy or with undesirable side effects.    
 Many researches in this area of study mentioned that the pharmacokinetic properties of 
benzimidazole family are represented by limited absorption (probably because of low 
solubility of this substances); maximum plasmatic concentration after 2-7 hours after oral 
administration; plasmatic level is not high than 1% from the administrated dose. Is important 
to mentioned that the food volume from the stomach influencing the bioavailability of the 
benzimidazole. Some researches consider that the mebendazole is not metabolized at high 
level, and the majority of the active ingredient is excreted unchanged thought digestive system 
after 24 hours. Between 5-10% is excreted through urinary system and a small quantity as 
mebendazole decarboxil metabolites (Burgat et al., 1983). Compared with this date, 
thiabendazole and cambendazole is rapidly metabolized in degradation products, so, less than 
1% from thiabendazole and 5% from cambendazole is excreted unchanged. The excretion of 
these substances can be observed in urine and excrement after 72 hours at thiabendazole and 
48 hours at cambendazole (Baggot and McKellar, 1994).  At monogastric animals, the 
oxibendazole is excreted through urinary system. After two day from benzimidazole 
treatment, in the majority of treated animal tissues, the benzimidazole residues are near to 






• The dogs healthy condition used in experiment, was appreciating using a minim kit 
of clinical and para-clinical investigations and those reveled physiological limits of 
clinical, hematological and biochemical parameters. 
• The pharmacokinetics of fenbendazole was characterized by reaching the maximum 
plasmatic concentration after oral administration in 1-2 hours with the limits 
between 104.7 and 8.2 ng/ml. 
• The half-time values have the variation between 2.77 and 13.81 hours according 
with the active ingredient dose. 
• The kidney clearance of fenbendazole revealed value between 101.98 l/hors and 
395.32 l/hours, those values being characteristic for the turnover and elimination of 
fenbendazole from the animal body. 
• General and statistic analyze of followed pharmacological parameters revel the 
possibility that the fenbendazole from this two products can be different metabolized 
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